SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (5021)7/29/1998 1:56:00 PM
From: scaram(o)uche  Respond to of 6136
 
>> how could these guys have so much information, including inside information, and get
swept along with the herd and make such ill-considered decisions? these guys are
getting paid obscene sums to evaluate companies and manage folks' money. ugh!

you can take this to the bank: the quality biotechs are not going away. The big hedge
funds can pound these little guys into a pile of rubble, and they'll continue working in
their basement labs. Wall Street can turn off their electricity and they'll fire up the
generator. Shut off the water, they'll turn on the treatment plant. These guys are *not*
going away. <<

Go, Peter!!



To: Peter Singleton who wrote (5021)7/29/1998 2:02:00 PM
From: billkirn  Read Replies (2) | Respond to of 6136
 
Peter: I think the reason behind this attitude is, not enough analyists to follow these companies and no matter how good, they will be invisible. There are too many companies and too few people to folow them. These guys also expect a serious consolidation of the biotech industry. Loosing perhaps 100 companies over the next few years.
Bill


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News